1. Home
  2. CUE vs VSME Comparison

CUE vs VSME Comparison

Compare CUE & VSME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • VSME
  • Stock Information
  • Founded
  • CUE 2014
  • VSME 2013
  • Country
  • CUE United States
  • VSME Hong Kong
  • Employees
  • CUE N/A
  • VSME N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • VSME
  • Sector
  • CUE Health Care
  • VSME
  • Exchange
  • CUE Nasdaq
  • VSME Nasdaq
  • Market Cap
  • CUE 61.1M
  • VSME 56.9M
  • IPO Year
  • CUE 2018
  • VSME 2023
  • Fundamental
  • Price
  • CUE $0.70
  • VSME $1.15
  • Analyst Decision
  • CUE Strong Buy
  • VSME
  • Analyst Count
  • CUE 2
  • VSME 0
  • Target Price
  • CUE $3.00
  • VSME N/A
  • AVG Volume (30 Days)
  • CUE 267.2K
  • VSME 1.0M
  • Earning Date
  • CUE 11-13-2025
  • VSME 04-14-2025
  • Dividend Yield
  • CUE N/A
  • VSME N/A
  • EPS Growth
  • CUE N/A
  • VSME N/A
  • EPS
  • CUE N/A
  • VSME N/A
  • Revenue
  • CUE $8,286,000.00
  • VSME $8,248,108.00
  • Revenue This Year
  • CUE N/A
  • VSME N/A
  • Revenue Next Year
  • CUE N/A
  • VSME N/A
  • P/E Ratio
  • CUE N/A
  • VSME N/A
  • Revenue Growth
  • CUE N/A
  • VSME 3.22
  • 52 Week Low
  • CUE $0.54
  • VSME $0.51
  • 52 Week High
  • CUE $1.99
  • VSME $3.21
  • Technical
  • Relative Strength Index (RSI)
  • CUE 39.09
  • VSME 33.58
  • Support Level
  • CUE $0.69
  • VSME $1.20
  • Resistance Level
  • CUE $0.81
  • VSME $1.67
  • Average True Range (ATR)
  • CUE 0.04
  • VSME 0.16
  • MACD
  • CUE -0.01
  • VSME -0.01
  • Stochastic Oscillator
  • CUE 6.00
  • VSME 15.40

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About VSME VS Media Holdings Limited

VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.

Share on Social Networks: